Discovery of altered protein profiles in epithelial ovarian carcinogenesis by SELDI mass spectrometry

Objective: Identification of proteomic alterations in epithelial ovarian tumorigenesis may facilitate the understanding of progression of this disease. Methods: Specific protein peak patterns were identified in 20 microdissected epithelial ovarian tumors (13 epithelial ovarian cancers (EOCs) and 7 low malignant potential (LMP) tumors), as well as in the matched normal cells. Protein profiles were generated by surface-enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF-MS) from all the different types of cells. Results: Among seven protein peaks from EOC cells, six were significantly increased while one was decreased compared with normal cells, and three peaks from LMP cells were markedly increased while one was decreased compared with normal cells. Conclusions: The combination of SELDI and laser capture microdissection (LCM) is effective in finding the key molecules in ovarian tumorigenesis. Further identification of these protein peaks is important and these malignant protein signatures lend themselves to identification Of Populations at high-risk for EOC and for monitoring response to EOC chemopreventive agents.

Epithelial ovarian cancer; Surface-enhanced laser desorption/ionization mass spectrometry (SELDI-MS); Laser capture microdissection (LCM)

[1] Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C. et al.: “Cancer statistics, 2006”. CA Cancer J. Clin., 2006, 56, 106.

[2] Scott M., McCluggage W.G.: “Current concepts in ovarian epithelial tumorigenesis: correlation between morphological and molecular data”. Histol. Histopathol., 2006, 21, 81.

[3] Craven R.A., Banks R.E.: “Laser capture microdissection and proteomics: possibilities and limitation”. Proteomics, 2001, 1, 1200.

[4] Yang C.Q., Chan K.Y., Ngan H.Y., Khoo U.S., Chiu P.M., Chan Q.K. et al.: “Single nucleotide polymorphisms of follicle-stimulating hormone receptor are associated with ovarian cancer susceptibility”. Carcinogenesis, 2006, 27, 1502.

[5] Chiang J.W., Karlan B.Y., Cass L., Baldwin R.L.: “BRCA1 promoter methylation predicts adverse ovarian cancer prognosis”. Gynecol. Oncol., 2006, 101, 403.

[6] Tammela J., Odunsi K.: “Gene expression and prognostic significance in ovarian cancer”. Minerva Ginecol., 2004, 56, 495.

[7] Yoshizaki T., Enomoto T., Nakashima R., Ueda Y., Kanao H., Yoshino K. et al.: “Altered protein expression in endometrial carcinogenesis”. Cancer Lett., 2005, 226, 101.

[8] Zhukov T.A., Johanson R.A., Cantor A.B., Clark R.A., Tockman M.S.: “Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry”. Lung Cancer, 2003, 40, 267.

[9] Cheung P.K., Woolcock B., Adomat H., Sutcliffe M., Bainbridge T.C., Jones E.C. et al.: “Protein profiling of microdissected prostate tissue links growth differentiation factor 15 to prostate carcinogenesis”. Cancer Res., 2004, 64, 5929.

[10] Petricoin E.F., Ardekani A.M., Hitt B.A., Levine P.J., Fusaro V.A., Steinberg S.M. et al.: “Use of proteomic patterns in serum to identify ovarian cancer”. Lancet, 2002, 359, 572.

[11] Zhang H., Kong B., Qu X., Jia L., Deng B., Yang Q.: “Biomarker discovery for ovarian cancer using SELDI-TOF-MS”. Gynecol. Oncol., 2006, 102, 61.

[12] Persson I.: “Estrogens in the causation of breast, endometrial and ovarian cancers-evidence and hypotheses from epidemiological findings”. J. Steroid. Biochem. Mol. Biol., 2000, 74, 357.

[13] Jones M.B., Krutzsch H., Shu H., Zhao Y., Liotta L.A., Kohn E.C. et al.: “Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer”. Proteomics, 2002, 2, 76.

[14] Petricoin E.F., Liotta L.A.: “SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer”. Curr. Opin. Biotechnol., 2004, 15, 24.

[15] Shih IeM., Kurman R.J.. “Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis”. Am. J. Pathol., 2004, 164, 1511.

[16] Ortiz B.H., Ailawadi M., Colitti C., Muto M.G., Deavers M., Silva E.G. et al.: “Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors”. Cancer Res., 2001, 61, 7264.

[17] Horiuchi A., Itoh K., Shimizu M., Nakai I., Yamazaki T., Kimura K. et al.: “Toward understanding the natural history of ovarian carcinoma development: a clinicopathological approach”. Gynecol. Oncol., 2003, 88, 309.

[18] Marquez R.T., Baggerly K.A., Patterson A.P., Liu J., Broaddus R., Frumovitz M. et al.: “Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon”. Clin. Cancer Res., 2005, 11, 6116.